CapsoVision to Release First Quarter 2026 Financial Results on May 14, 2026

About this update from Capsovision, Inc.

[{"type":"image","alt":"CapsoVision","displaySize":"","headline":null,"caption":"CapsoVision","className":"","disableSlideshowImg":false,"size":{"original":{"width":289,"height":82,"url":"https://media.zenfs.com/en/globenewswire.com/7997fdcf01bc3e4679fd070889da0319"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/SIaZW6hQ7uLjpz9n25nq0w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOQ--/https://media.zenfs.com/en/globenewswire.com/7997fdcf01bc3e4679fd070889da0319","width":289,"height":82}},"lazy":false},{"type":"text","content":"SARATOGA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the Company will release first quarter 2026 financial results on Thursday, May 14, 2026, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update.","length":510,"tagName":"p"},{"type":"text","content":"Investors interested in listening to the conference call may do so by dialing (800) 715-9871 or (646) 307-1963 and referencing conference ID 5439091. The live and archived webcast of the conference call can be found on the Events page in the Investor Relations section of CapsoVision’s website.","length":294,"tagName":"p"},{"type":"text","content":"About CapsoVision","length":17,"tagName":"p"},{"type":"text","content":"CapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions to transform the detection and screening of gastrointestinal diseases. Its flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video retrieval. The Company’s next pipeline product, CapsoCam Colon™ with enhanced AI, is designed to enable non-invasive colon imaging and polyp detection. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics. For more information on CapsoVision, please visit www.capsovision.com.","length":802,"tagName":"p"},{"type":"text","content":"Investor Relations C...

More updates from Capsovision, Inc.